Perigon Wealth Management LLC Acquires New Shares in IQVIA Holdings Inc. $IQV

Perigon Wealth Management LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,578 shares of the medical research company’s stock, valued at approximately $498,000.

A number of other hedge funds also recently made changes to their positions in the stock. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the 4th quarter valued at $27,000. Finally, CrossGen Wealth LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at $28,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Robert W. Baird upped their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Mizuho boosted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

Insider Activity at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. Insiders own 1.70% of the company’s stock.

IQVIA Stock Up 4.0%

Shares of IQVIA stock opened at $249.62 on Thursday. The firm has a market cap of $41.09 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 2.04 and a beta of 1.18. The stock’s 50-day moving average is $210.23 and its 200 day moving average is $186.82. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.